Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

  • ID: 3837876
  • Report
  • 374 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Bionomics Limited
  • Eisai Co., Ltd.
  • Immunicum AB
  • Merck KGaA
  • Pfizer Inc.
  • MORE
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Summary

‘Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016’, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Bionomics Limited
  • Eisai Co., Ltd.
  • Immunicum AB
  • Merck KGaA
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metastatic Renal Cell Carcinoma Overview

Therapeutics Development

Pipeline Products for Metastatic Renal Cell Carcinoma - Overview

Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis

Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies

Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes

Metastatic Renal Cell Carcinoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Metastatic Renal Cell Carcinoma - Products under Development by Companies

Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes

Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development

Acceleron Pharma, Inc.

Amgen Inc.

Argos Therapeutics, Inc.

Astellas Pharma Inc.

Bayer AG

Bionomics Limited

Bionovis SA

Bristol-Myers Squibb Company

Cellceutix Corporation

Celldex Therapeutics, Inc.

Cerulean Pharma, Inc.

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Exelixis, Inc.

Gene Techno Science Co., Ltd.

Genor BioPharma Co., Ltd.

Immune Design Corp.

Immunicum AB

Incyte Corporation

Mabion SA

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Mycenax Biotech Inc.

NewLink Genetics Corporation

Novartis AG

Oncobiologics, Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

Peloton Therapeutics, Inc.

Pfizer Inc.

Prima BioMed Ltd.

Rexahn Pharmaceuticals, Inc.

Richter Gedeon Nyrt.

Seattle Genetics, Inc.

Sevion Therapeutics, Inc.

Syndax Pharmaceuticals Inc

Taiwan Liposome Company, Ltd.

Tocagen Inc.

TVAX Biomedical, Inc.

Tyrogenex, Inc.

Metastatic Renal Cell Carcinoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AGS-16C3F - Drug Profile

avelumab - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

bevacizumab biosimilar - Drug Profile

BNC-105 - Drug Profile

cabozantinib s-malate - Drug Profile

capmatinib - Drug Profile

CDX-014 - Drug Profile

Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile

Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile

crizotinib - Drug Profile

CRLX-101 - Drug Profile

dalantercept - Drug Profile

durvalumab - Drug Profile

emibetuzumab - Drug Profile

entinostat - Drug Profile

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

G-305 - Drug Profile

IMP-321 - Drug Profile

INCAGN-1876 - Drug Profile

Intuvax - Drug Profile

ipilimumab - Drug Profile

KM-3174 - Drug Profile

lenvatinib mesylate - Drug Profile

LY-2510924 - Drug Profile

Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile

nivolumab - Drug Profile

Orellanine - Drug Profile

panobinostat - Drug Profile

pazopanib hydrochloride + pembrolizumab - Drug Profile

pembrolizumab - Drug Profile

PT-2385 - Drug Profile

radium Ra 223 dichloride - Drug Profile

Recombinant Protein for Oncology - Drug Profile

rocapuldencel-T - Drug Profile

RX-0201 - Drug Profile

sapanisertib - Drug Profile

SGN-CD70A - Drug Profile

Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile

SNX-5422 - Drug Profile

SVN-002 - Drug Profile

TLC-388 - Drug Profile

trebananib - Drug Profile

TVI-Kidney-1 - Drug Profile

varlilumab - Drug Profile

X-82 - Drug Profile

Metastatic Renal Cell Carcinoma - Dormant Projects

Metastatic Renal Cell Carcinoma - Discontinued Products

Metastatic Renal Cell Carcinoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016

Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016

Metastatic Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2016

Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016

Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016

Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016

Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016

Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2016 356List of Figures

Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016

Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Bionomics Limited
  • Eisai Co., Ltd.
  • Immunicum AB
  • Merck KGaA
  • Pfizer Inc.
  • MORE
According to our recently published report 'Metastatic Renal Cell Carcinoma – Pipeline Review, H2 2016'; Metastatic Renal Cell Carcinoma pipeline therapeutics constitutes close to 55 molecules. Out of which approximately 52 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Metastatic Renal Cell Carcinoma The metastatic stage of the renal cell carcinoma occurs when the disease invades and spreads to other organs. It is most likely to spread to neighboring lymph nodes, the lungs, the liver, the bones, or the brain. Symptoms include abdominal pain and swelling, back pain, blood in the urine, swelling of the veins around a testicle (varicocele) and weight loss. Radiotherapy and chemotherapy have less of a role in therapy of renal cell carcinoma then in other malignancies; but they are still sometimes used in treatment of metastatic renal cell carcinoma.

The report 'Metastatic Renal Cell Carcinoma – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 21, 14, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Acceleron Pharma, Inc.
Amgen Inc.
Argos Therapeutics, Inc.
Astellas Pharma Inc.
Bayer AG
Bionomics Limited
Bionovis SA
Bristol-Myers Squibb Company
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cerulean Pharma, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
Gene Techno Science Co., Ltd.
Genor BioPharma Co., Ltd.
Immune Design Corp.
Immunicum AB
Incyte Corporation
Mabion SA
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Mycenax Biotech Inc.
NewLink Genetics Corporation
Novartis AG
Oncobiologics, Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Peloton Therapeutics, Inc.
Pfizer Inc.
Prima BioMed Ltd.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Syndax Pharmaceuticals Inc
Taiwan Liposome Company, Ltd.
Tocagen Inc.
TVAX Biomedical, Inc.
Tyrogenex, Inc
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll